Literature DB >> 29446061

Viewpoints of dentists on the use of bisphosphonates in rheumatology patients.

Coline Daron1, Christophe Deschaumes2, Martin Soubrier1, Sylvain Mathieu1.   

Abstract

OBJECTIVES: Alhough typically prescribed in oncology, bisphosphonates (BPs) are also employed in rheumatology, particularly for the treatment of osteoporosis, sometimes resulting in complications, such as osteonecrosis of the jaw. Because of different opinions between rheumatologists and dentists on BP use, this study aimed to assess the views of dentists regarding administration of BPs in rheumatology.
METHODS: A questionnaire was sent to 880 dentists from the Auvergne region of France to determine their views on BP treatment.
RESULTS: We obtained 382 (43.4%) responses and analysed 376 (58.7% men). In total, 156 (41.5%) of the responders analysed had attended an in-service training course (ISTC) on the topic. A total of 237 (63.0%) systematically inquired as to whether their patients were undergoing BP treatment; this proportion was higher among those who had been practicing for fewer than 10 years (P < 0.004). For patients receiving BPs, 84.5% of practitioners felt ill at ease about performing dental surgery (n = 318) and 11% felt ill at ease about performing nonsurgical dental care (n = 41); 67% stated that their practice differed depending on the method of BP administration (per os or intravenously). Overall, 53.7% of practitioners felt uncomfortable when asked by a rheumatologist whether a given patient's dental status permitted prescription of BP (n = 202). This proportion was higher among those who had never attended an ISTC (62.6% vs. 50.7%; P < 0.03).
CONCLUSIONS: Dentists feel ill at ease providing dental surgery to patients receiving BPs. Closer collaboration and better information-sharing between rheumatologists and dentists is necessary to facilitate the administration of BPs in rheumatology.
© 2018 FDI World Dental Federation.

Entities:  

Keywords:  Bisphosphonates; dentists; questionnaire; rheumatology; viewpoints

Mesh:

Substances:

Year:  2018        PMID: 29446061      PMCID: PMC9378899          DOI: 10.1111/idj.12363

Source DB:  PubMed          Journal:  Int Dent J        ISSN: 0020-6539            Impact factor:   2.607


  29 in total

1.  Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.

Authors:  Aliya A Khan; Lorena P Rios; George K B Sándor; Nazir Khan; Edmund Peters; Mohammed O Rahman; Cameron M L Clokie; Edward Dore; Sacha Dubois
Journal:  J Rheumatol       Date:  2011-04-15       Impact factor: 4.666

2.  Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition?

Authors:  P Diz; J Limeres; S Fedele; J Seoane; M Diniz; J F Feijoo
Journal:  Med Hypotheses       Date:  2011-12-02       Impact factor: 1.538

3.  A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?

Authors:  J E O'Connell; O Ikeagwani; G J Kearns
Journal:  Ir J Med Sci       Date:  2012-01-06       Impact factor: 1.568

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 5.  Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.

Authors:  Stuart L Silverman; Regina Landesberg
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

6.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

Review 7.  Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.

Authors:  Carolyn J Crandall; Sydne J Newberry; Allison Diamant; Yee-Wei Lim; Walid F Gellad; Marika J Booth; Aneesa Motala; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

Review 8.  Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

Authors:  M E Sarasquete; M González; J F San Miguel; R García-Sanz
Journal:  Oral Dis       Date:  2009-04-22       Impact factor: 3.511

9.  General practitioner management of shoulder pain in comparison with rheumatologist expectation of care and best evidence: an Australian national survey.

Authors:  Rachelle Buchbinder; Margaret P Staples; E Michael Shanahan; Juliana F Roos
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 10.  Using the Internet for surveys and health research.

Authors:  Gunther Eysenbach; Jeremy Wyatt
Journal:  J Med Internet Res       Date:  2002 Apr-Nov       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.